Albert D. Friesen holds a Ph.D. in Protein Chemistry from the University of Manitoba. As the first full time employee and President of the Winnipeg Rh Institute he oversaw the development and initial pharmaceutical approval of WinRho. Dr. Friesen has also been instrumental in founding several health industry companies including Novopharm Biotech Inc. (now Viventia Biotech Inc.), Genesys Pharma Inc., and KAM Scientific Inc. In 1997, he co-founded Medicure Inc. and currently serves as the Company's President, CEO and Chairman.

Dr. Friesen's noteable achievements include the establishment of several GMP production facilities for the production of human pharmaceuticals. He has also managed and initiated the research and clinical development of numerous pharmaceutical candidates, including more than 15 INDs and 2 successful NDAs. Dr. Friesen is a founder of the Industrial Biotechnology Association of Canada (IBAC) and past Chairman of its Board of Directors. He has been a member of the Industrial Advisory Committee to the Biotechnology Research Institute in Montreal. Dr. Friesen has an extensive network within the international biotechnology and corporate finance communities.